Long-term complications Could Improve by Image-Guided Treatment for deep vein thrombosis aredeep venous thrombosis is a serious disease which is the formation of a blood clot within a deep vein, usually in the legs http://tadacip20mg.net . A patient with DVT is typically treated with anticoagulants , but researchers have found that image – guided interventional radiology procedures may role in role in the long-term treatment of DVT, according to a study in the October issue of of published American Journal of Roentgenology . DVT is estimated to occur in nearly one million people per year in the United States alone, said Suresh Vedantham, lead author. The anticoagulant treatment is pulmonary embolism to prevent good, but it does not completely destroy prevent a blood clot or a patient from developing long-term complications – including chronic, daily leg pain, swelling, changes in skin color, and open wounds, said Dr. Vedantham. Image-guided pharmacomechanical catheter thrombolysis that was used until recently as a rule, only the most treat DVT cases, involves the delivery of a clot busting drug through a catheter-mounted device that also chews up of a clot – eliminating it completely and may improving a patient’s long-term outcome and preventing of future events If this technique is proven to prevent long-term DVT complications and improve patient outcomes, it only makes sense several several patients with DVT . He said. Most patients with DVT do not know that image-guided treatment options available so it is important to referring to referring physicians and radiologists more because the patients really benefit from these procedures, said Dr. Vedantham.
This study appears in the October issue of the American Journal of Roentgenology.neublastin. Is phase I clinical development as a novel treatment for neuropathic painNsGene A / S announced that neublastin, a proprietary therapeutic protein NsGene has been licensed Biogen Idec[ NASDAQ: BIIB] in the peripheral nervous system, has used in the phase I clinical trials for the treatment of neuropathic pain. The first patient in the Phase I trial was dosed at the University of Adelaide in Australia. A total of 28 patients are expected to be in the study, performed and is sponsored by Biogen Idec in order to be enrolled to evaluate the safety and tolerability of neublastin. The initiation of the Phase I clinical trial triggers a milestone payment from Biogen Idec NsGene. Teit E. Johansen, CEO NsGene, said: ‘The initiation of this Phase I trial is a significant milestone for NsGene since neublastin is the first application of our unique pipeline of proprietary neurotrophic factors to the clinical important transition into the history history. ”We are thrilled with the successful collaboration with Biogen Idec. Now stands now stands as one of the most promising and exciting product opportunities for the treatment of neuropathy and associated pain, targeting millions of patients with unmet medical needs, ‘added Lars U. Wahlberg, COO of NsGene. Read more…